Phaseline

Targets › SLC30A1

SLC30A1 (Proton-coupled zinc antiporter SLC30A1): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 4; Metabolic and endocrine, Genitourinary, Other; next expected readout Dec 2026.

Zinc ion:proton antiporter that could function at the plasma membrane mediating zinc efflux from cells against its electrochemical gradient protecting them from intracellular zinc accumulation and toxicity. Alternatively, could prevent the transport to the plasma membrane of CACNB2, the L-type calcium channels regulatory subunit, through a yet to be defined mechanism. (UniProt, Q9Y6M5)

Open in Phaseline: the race on SLC30A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Augusta University3 mg/day Zinc Supplementation
Zinc supplementation (higher dose)
SLC30A1Phase 4Extreme Prematurity,Extremely Low BirthweightMay 2027
Endeavor HealthZinc Citrate Oral Capsule with phytase
Zinc supplementation with phytase co-factor to enhance zinc bioavailability
SLC30A1Phase 2Overactive Bladder (OAB)Dec 2026
Quaid-e-Azam Medical CollegeZinc sulfate
Zinc supplementation - cofactor for bilirubin metabolism and antioxidant support
SLC30A1Phase 2Indirect Hyperbilirubinemia–
Universitas IndonesiaZinc, Chromium, Vitamin C, and Copper Supplementation
Combination mineral and vitamin supplement: zinc enhances insulin signaling and glucose me
SLC30A1, CREBBP, SLC31A1Phase 2PreDiabetes–

Conditions

Overactive Bladder (OAB) (1) Indirect Hyperbilirubinemia (1) PreDiabetes (1) Extreme Prematurity,Extremely Low Birthweight (1)

Modalities

small molecule (3)

Companies

Endeavor Health (1) Quaid-e-Azam Medical College (1) Universitas Indonesia (1) Augusta University (1)

Related targets

CREBBP (1) SLC31A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.